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Abstract: Introduction: Proton pump inhibitors can influence glucose-insulin homeostasis by elevating plasma gastrin.
Considering the few clinical trials and contradictory results of previous studies, we aimed to evaluate the effect of
omeprazole, a proton pump inhibitor, on glucose-insulin homeostasis in patients with type 2 diabetes mellitus
(T2DM). Materials and Methods: In this before-after clinical trial, 40 patients with T2DM received omeprazole
treatment for 12 weeks. Patients were asked to continue their diet, lifestyle, and physical activity throughout
the study period. Glycosylated hemoglobin (HbA1c), fasting plasma sugar (FBS), insulin level, C-peptide and 2
hours post prandial blood sugar (2hppBS) were measured at baseline and after 12 weeks. Homeostatic model
assessment of Insulin resistance (HOMA-IR) and homeostatic model assessment of β-cell dysfunction (HOMA-
B) indices were also calculated at baseline and after 12 weeks of omeprazole administration. Results: After 12
weeks of omeprazole administration, there was a clear decrease in the mean HbA1C before (8.11±0.96) and after
(7.13±0.68) the treatment (P<0.001). Similarly, a decrease in mean FBS and 2HPPBS before and after treatment
was observed, which was statistically significant for FBS (P=0.01) but not for 2HPPBS (P=0.1). There was a clear
increase in the level of Insulin (P=0.001) and C-peptide (P=0.003). The mean activity index of HOMA-B before
and after receiving omeprazole was 54.41±27.06 and 79.24±45.32, respectively (P=0.007). Also, HOMA-IR index
was 5 before, and 6 after receiving omeprazole (P=0.001). Conclusion: Administration of omeprazole, increases
insulin levels and decreases the levels of HbA1c, FBS, thus improving glycemic status and can be combined with
other drugs used to manage DM, especially in patients with gastrointestinal problems; but more studies are
needed.
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1. Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder that
has a high prevalence worldwide. In 2019, 463 million peo-
ple with DM lived worldwide, which is estimated to reach 700
million by 2045 (1). These predictions indicate a sharp in-
crease in DM, especially in developing countries. In fact, we
are facing a global epidemic.
DM is a chronic disease with complex pathophysiology that
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does not involve only insulin deficiency in type 1 DM and
insulin resistance and progressive loss of pancreatic beta
cells in type 2; but other pathophysiologies include increased
lipolysis, decreased or resistance to incretin hormones, hy-
perglucagonemia, increased renal glucose uptake, and brain
resistance to insulin (2). But ultimately hyperglycemia in
type 1 and type 2 DM is the result of a partial or complete
defect of pancreatic beta cells (3) and therefore research on
pancreatic beta cell regeneration is being actively investi-
gated.
The history of diabetes treatment and glycemic control
shows that more than one treatment is often needed for pa-
tients at any one time, and effective treatment requires multi-
ple medications; which is used in combination to correct dif-
ferent pathophysiological defects. Effectiveness of the drugs,
their adverse effects, tolerability and cost-effectiveness are
also important criteria for drug selection (4). Also, it should
always be kept in mind that some drugs are not recom-
mended because we do not have enough information about
their side effects. Therefore, any new treatment strategy with
the above characteristics can be a good event (3).
DM affects many organs with chronic microvascular com-
plications (retinopathy, neuropathy, and nephropathy),
macrovascular complications (Coronary artery disease, pe-
ripheral and cerebrovascular disease) and non-vascular
complications including gastrointestinal, urogenital and skin
involvement, cataract, glaucoma, hearing loss and infection
(5).
Studies have shown that careful control and evaluation of
blood sugar, proper treatment of DM and achieving plasma
glucose in the normal range delays the onset and progression
of micro and macrovascular complications (6, 7).
Therefore, glycosylated hemoglobin (HbA1C) is used as the
gold standard for diagnosis (8) and evaluation of blood glu-
cose and a criterion for estimating the severity of DM com-
plications (9, 10). In HbA1C, the beta chains of hemoglobin
A1 bind to glucose in a non-enzymatic reaction, showing the
average blood glucose over the last 8 to 12 weeks (11, 12).
Gastrin, as the main endocrine-regulating hormone in re-
sponse to secretory activities, after consumption of protein
foods (13, 14) and is said to have a trophic effect on beta cells.
In mice, gastrin induces neogenesis of pancreatic beta cells
(15, 16). In vitro studies also showed that this hormone in-
crease β cell mass (17).
The main site of gastrin secretion is the antrum of the stom-
ach by G cells. But the other parts also secrete gastrin to
a lesser extent in response to intestinal stimulation (pres-
ence of amino acids and amine-containing diet). Gastrin is
the first released incretin hormone in response to oral glu-
cose intake and enhances glucose-dependent insulin secre-
tion (18). Because the amount of gastrin released by oral
glucose to stimulate beta cell secretion is very low, the mo-
tivation for research on gastrin as an incretin hormone was
diminished for decades until recent studies showed inter-
ference between gastrointestinal hormones. As well as gas-
trin can cause normoglycemic conditions in diabetic rats.
But gastrin has been shown to affect insulin secretion many
times in previous studies (19). On the other hand, proton
pump inhibitors (PPIs) are drugs used to treat stomach acid-
related diseases, especially gastroesophageal reflux disease.
Other uses for PPIs include the treatment and prevention of
NSAID-induced ulcers, gastritis, gastric ulcer and duodenal
ulcer, part of Helicobacter pylori eradication therapy, hemor-
rhagic gastric ulcer, and functional dyspepsia (20, 21). They
lower acid levels and therefore cause relative hypergastrine-
mia; which may cause better control of hyperglycemic status.
Based on this hypothesis, the question arises as to whether
PPI treatment is associated with better control of glycemic
status in people with type 2 DM.
Safety in the long-term use of PPIs is more reported in
omeprazole. Reports indicate that omeprazole has been safe
for 15 years. However, there are some side effects including
hypochlorhydria (15).
The risk of hypomagnesemia has also been reported in long-
term use of PPI in some cases, and prolonged use of omepra-
zole has impaired the absorption of Vitamin B12 (20). Sec-
ondary hypergastrinemia caused by PPI can be considered
a tumor carcinoid. However, long-term use (11 years) of
omeprazole has been safe (22).
Recent studies have shown that gastrin, like other incretin
hormones such as GLP1, stimulates pancreatic beta cell pro-
liferation and neogenesis in animal and human cells, and
also appears to increase insulin levels up to 2 times at the
same time as glucose uptake (19, 23).
In one study, three days of intravenous injection of exoge-
nous gastrin increased the beta cell mass of pancreatic islets
in mouse samples and continued injection from 7 to 10 days
later doubled the mass of beta cells which were examined by
morphometry (15). In another study, they showed that the
combination treatment of GLP 1 and gastrin expanded the
mass of human beta cells implanted in diabetic immunode-
ficient mice and that it improved the hyperglycemic status.
Improved hyperglycemia was associated with increased in-
sulin levels in grafted pancreatic cells and was equally asso-
ciated with increased plasma C-peptide levels (24). A study
demonstrated that combination therapy of Dipeptidyl pep-
tidase inhibitor 4 (DDPi4), such as sitagliptin, linagliptin
which increase GLP1 levels, with PPIs, reversed type 1 DM
in the non-obese diabetic (NOD) mouse model. Treatment
with DDPi4 improved glycemic status in 38%, PPIs in 33%,
and their combination improved glycemic status in 75% of
them. Unlike administration of either alone, their combina-
tion showed a significant increase in C-peptide level (25).
Also, in 2011, the same study group demonstrated that com-
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bination therapy with sitagliptin and pantoprazole induced
neogenesis of grafted human beta cells in diabetic rats (25).
After these basic studies on animals, several studies were per-
formed on humans. In a cross-sectional study of 347 patients
with type 2 DM, the HbA1C level in the group who took PPI
was 7% and in the group who did not take PPI was 6%, which
was significantly lower (22).
Boj-Carceller and co-workers in two separate studies, one
study for people with type 1 and 2 poor control DM and the
other study for people with controlled type 2 DM, both of
which were cross-sectional studies performed on admitted
patients, achieved similar results. In the first study, a smaller
sample of 72 patients, 33.8% of whom had type 1 DM, showed
that patients receiving PPI had lower HbA1C levels than those
who did not. This was especially evident in people with type
2 DM who did not receive insulin (26). In the second study
on 97 patients with controlled type 2 DM, 54 patients receiv-
ing PPI had HbA1C level of 6.7%, compared to 7.3% in 43 pa-
tients who did not receive PPI, which was statistically signifi-
cant (27).
Another study on a small cross-sectional study on 42 peo-
ple with type 2 DM who had gastrointestinal problems and
had been on long-term treatment with esomeprazole in com-
parison with those who did not receive PPIs, achieved simi-
lar results; HbA1C decreased by 0.7% in patients with type 2
DM who received esomeprazole versus 0.2% reduction in pa-
tients with DM who did not receive PPIs. In patients with un-
controlled DM (HbA1C more than 9%), the beneficial effects
of esomeprazole were more pronounced, showing a 1.2% de-
crease in HbA1C levels (P=0.004) (28).
Another study showed that omeprazole administration for
12 weeks was associated with a significant improvement in
glycemic control based on the FBS and HbA1C level of the
patients (29). In contrast, another study on patients with type
2 DM did not show a statistically significant difference be-
tween the PPI and control group and concluded that PPI ad-
dition does not affect glycemic control (30). Kruszelnicka and
colleagues showed that PPI use is not associated with altered
glycaemia in patients with cardiovascular disease based on
baseline glucose levels and 2 hours post glucose intake levels
of the patients (31).
Considering that few studies have been done in this field,
most of them are retrospective studies and only studied the
effect of PPI on HbA1C level and other parameters of glucose-
insulin homeostasis (FPG, Insulin level, C-Peptide, HOMA-B
, HOMA-IR) were not assessed in most of them, their con-
tradictory results, and no similar study in Iran (considering
its geographical, racial, cultural and nutritional and lifestyle
differences), we decided to consider the effect of PPIs on
glycemic control in a before-after clinical trial study on pa-
tients with type 2 DM referred to the endocrinology clinic of
Imam Hossein Hospital. Among PPIs, omeprazole was used
in the study because of its safety in long-term use (even up to
15 years) and has a lower cost for patients.
2. Materials and Methods
2.1. Study design
This study is a before-after clinical trial. It was performed on
adult patients with type 2 DM referred to the endocrinology
clinic of Imam Hossein Hospital during 2020. The sample
size was calculated based on previous studies and their data
were estimated to be 40 people. After providing explanations
for the patient to participate in the research project, and
mentioning that no fee would be received, informed consent
was obtained and the study was approved by the Ethics
Committee.
Inclusion criteria were adults of both sexes with diagnosis
of type 2 DM according to World Health Organization cri-
teria whose diabetes was not newly diagnosed and were on
maintenance doses of oral anti-diabetic drugs, metformin or
sulfonylurea, or both for at least one month.
Exclusion criteria were previous and current use of insulin,
pioglitazone or treatment with incretins, history of liver
failure (liver enzyme levels more than three times the normal
limit), kidney disease (Creatinine>1.5), any complications of
DM, alcohol consumption and drugs, hemoglobinopathies,
pregnant and lactating women and people who already had
used PPIs.
After obtaining the informed consent, questionnaires con-
taining background and demographic information including
age, sex, weight, height, body mass index (BMI), education
level and place of residence (city/village) were recorded.
Enrolled patients were asked to go to the laboratory in the
fasting state for measuring complete blood count (CBC),
blood urea nitrogen (BUN), Creatinine (Cr), fasting blood
sugar (FBS), hemoglobin A1c (HbA1C), C-peptide, and
insulin level in the fasting venous blood sample. Two hours
later, the patient underwent venous blood sampling for 2
hours post prandial blood sugar (2hppBS).
Patients were then given omeprazole 20 mg capsules twice
daily orally and asked to continue their usual diet, lifestyle,
physical activity, and medication during the study. Patient
compliance was assessed based on their visits or telephone
calls and the number of capsules consumed. Those who
took more than 80% of the capsules were considered to have
compliance and their test results were examined. Patients
were prescribed omeprazole for 3 months and were asked
to return to the clinic with the results of re-testing FBS,
HbA1C, 2hppBS, C-peptide, and insulin level. To prevent
glycolysis, plasma was isolated up to one hour after blood
sampling and plasma glucose was measured enzymatically
by glucose oxidase. HbA1c was also measured by Bronate
Affinity Choromatography using NYCOCARD kit and fasting
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insulin and c-peptide levels were assessed by Immunoreac-
tive method.
Homeostatic model assessment of Insulin resistance
(HOMA-IR) and homeostatic model assessment of β-
cell dysfunction (HOMA-B) indices were also calculated




The data collected from the checklists were edited in SPSS
software, version 18, and descriptively analyzed by paired
and independent t tests. P values of 0.05 or less were con-
sidered statistically significant.
3. Results
In this study 40 patients participated, of which 8 (20%) pa-
tients were excluded (loss to follow-up) because of non-
recurrence, testing and consumption of less than 80% of
omeprazole capsules prescribed by the study. The time of
evolution of DM in participants was up to 5 years. Of the
remaining 32 patients (follow-up group), 12 (37.5%) were
men and 20 (62.5%) were women. Their mean±SD age was
54.34±10.85 years (Figure 1).
Of the eight patients who discarded the study, 3 (37.5%)
were men and 5 (62.5%) were women. Their mean±SD age
was 52.87±8.32 years. The mean difference between the two
groups was not statistically significant (P=0.724). Also, all
other parameters including the mean initial values of BMI,
FBS, 2HPPBS, C-peptide, and HbA1C and fasting Insulin level
were not statistically different from the remaining group (Ta-
ble 1). Table 2 shows the education level of all 40 study par-
ticipants and the remaining 32 patients (follow-up group).
After 12 weeks of treatment with omeprazole, there was a
clear decrease in the mean HbA1C before (8.11±0.96) and af-
ter (7.13±0.68) the treatment (P<0.001). Similarly, a decrease
in mean FBS, 2HPPBS before and after treatment was ob-
served, which was statistically significant in FBS (P=0.01) but
not significant in 2HPPBS (P=0.1). There was a clear increase
in the level of insulin (P=0.001) and C-peptide (P=0.003) (Ta-
ble 3, Figure 2).
Changes in insulin level and HbA1c in the follow-up group is
shown in Figure 3, both of which were significant (P=0.001).
The mean activity index of HOMA-B before and after receiv-
ing omeprazole was 54.41±27.06 and 79.24±45.32, respec-
tively (P=0.007). Also, HOMA IR index was 5 before, and 6
after receiving omeprazole (P=0.001) (Figure 4).
4. Discussion
The main goal of health care systems around the world is to
promote the health and treatment of patients with the help
of the most effective methods and treatments.
According to American Diabetic Association, in 2018, 34.2
million Americans or 10.5% of the population had DM which
about 32.6 million had type 2 DM. Although DM may be un-
derreported as a cause of death, it was the seventh leading
cause of death in the United States in 2017 (32).
Statistics from the International Diabetes Federation also
showed that in 2019, approximately 463 million adults were
living with DM and this will rise to 700 million by 2045. The
proportion of people with type 2 DM is increasing in most
countries and 374 million people are at increased risk of de-
veloping type 2 DM. Also, DM caused 4.2 million deaths and
at least 760 billion dollars in health expenditure in 2019 (1).
According to these statistics, controlling DM and its compli-
cations is the only way to deal with it. Studies have shown
that careful control and evaluation of blood sugar, proper
treatment of DM and achieving plasma glucose in the nor-
mal range delays the onset and progression of micro and
macrovascular complications.
HbA1c is the best parameter for assessing glycemic status
and evaluating the effect of anti-diabetic drugs. A meta-
analysis showed that PPI administration may not gener-
ally have a significant effect on reduction of HbA1C level
in patients with type 2 DM, but pantoprazole administra-
tion showed significant reduction of HbA1C level, which in
turn demonstrates the effect of PPI type on its influence on
glycemic control. However, none of the nine studies reviewed
in this review addressed the effects of omeprazole, as a PPI,
on glycemic control. Also, bias sources such as the exclusive
inclusion of men were detected and the article itself pointed
to the need for further studies (33).
Based on information available so far, our study was the first
clinical trial study in Iran that was performed by Before- After
method and investigated the effect of omeprazole treatment
on glucose-insulin homeostasis in patients with type 2 DM.
In our study 40 people participated, of which 8 (20%) were
excluded from the study for various reasons, including not
performing the second test, not taking 80% of the prescribed
omeprazole, discontinuation of the drug by the patient’s fam-
ily doctor due to lack of knowledge about the presence of the
patient in our study, distance to return to the clinic and a case
of drug intolerance. Since they were no more than 20% of the
study population, and also there was no statistically signifi-
cant difference compared with 32 remaining participants in
terms of demographic characteristics and other parameters
in our study, so their removal did not affect our study and we
continued with the remaining 32 patients.
Omeprazole treatment for 12 weeks clearly reduced HbA1c
levels by 0.97% and increased insulin levels by 4.01µU/ml,
changes similar to those observed in a study by Singh and
colleagues (18).
In our study, the mean HbA1c level decreased from 8.1±0.96
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to 7.1±0.68, which was statistically significant (P<0.001). Also,
in a study performed in India as a Double Blind RCT on 31
patients (16 in the pantoprazole group and 15 in the placebo
group) HbA1c level decreased from 7.6±1.17 to 6.8±1.16 and
was statistically significant (P<0.001) (18).
We also measured fasting insulin and blood sugar levels,
HOMA-B cell and HOMA IR indices. In the previously men-
tioned study, similar results were obtained, but changes in
gastrin levels were examined, which were not addressed in
our study due to the high cost. However, C-peptide and
2HPPBS were considered in our study but they were not men-
tioned in theirs. Table 4 shows a complete comparison of the
current study and the mentioned study. Many of the findings
of our study are in line with Singh’s study and to our knowl-
edge, it is the only study similar to ours in terms of inclusion
and exclusion criteria, but the rest of the studies did not fol-
low these points.
One study was based on electronic records of patients with
type 2 DM taking PPIs and those not taking them, and the
HbA1C levels were reported 7.1% and 7.7%, respectively (34).
This value was 8.1% vs. 7.1% in our study. However, they did
not specify the duration of PPI use.
A previous cross-sectional study found similar results in pa-
tients with type 2 DM with gastrointestinal problems who
had been on long-term treatment with esomeprazole and
those who did not receive PPI, i.e., HbA1C reduction of 0.7%
in patients with type 2 DM receiving esomeprazole versus re-
duction of 0.2% in patients with DM who did not receive PPI
(28).
Other studies have been performed in this field but none of
them examined FBS, 2HPPBs, Insulin, C-peptide and HOMA-
B and HOMA-IR indices. And most of these studies were ret-
rospective but the type of our study, before-after clinical trial,
and the study of these parameters were the advantages over
other studies.
Regarding HOMA-IR and HOMA-β indices that were dis-
cussed in our study and other studies except Singh’s study,
it should be said that these two valid and practical indices
show insulin resistance and beta cell performance respec-
tively, and are calculated based on fasting blood sugar and
insulin through mathematical formulas.
The values attributed to these indicators have been ex-
pressed differently in various studies. In one of them, the
HOMA-β cell index was expressed 100% in a young person
under 35 years with normal weight. In the same study, the
HOMA-IR index was expressed as less than 3 (normal resis-
tance), 3 to 5 (moderate resistance), and higher than 5 (sever
resistance) (35).
In our study, after 12 weeks of omeprazole, the HOMA-β cell
index improved significantly, but the HOMA IR index also in-
creased, which was also statistically significant. However, in
one study, the changes in this index were not statistically sig-
nificant (18). This difference may be due to racial influence
and differences in the effect of omeprazole and requires fur-
ther investigation.
But it is certain that the insulin resistance index in our pa-
tients was much higher than in Indian patients in Singh’s
study and was in the range of severe resistance. However,
omeprazole was able to meet our expectations of improving
beta cell function, which may be due to stimulation of gastrin
secretion as an incretin hormone following omeprazole con-
sumption and therefore the effect of this increase in gastrin
level on stimulating beta cells and insulin secretion or beta
cell proliferation.
In another study, administration of lansoprazole in Psam-
momys obesus mice with type 2 DM for 17 days in differ-
ent doses and measurement of morning blood glucose, in-
sulin, and gasterin, showed that gastrin levels increased by
9-fold, glucose levels decreased significantly, and insulin lev-
els increased. Also, a 50% increase in the volume of beta-cell
masses was reported which could further strengthen the idea
that there is a close relationship between PPI and gastrin and
glucose-insulin homeostasis (19).
Perhaps another reason for the effect of omeprazole in lower-
ing HbA1c levels and improving glycemic status in our study
is the effect of this drug and other PPIs in other studies on
delayed gastric emptying following food intake. This leads to
the timely delivery of glucose to the ileum and thus, if the en-
vironment is favorable, causes the secretion of incretin hor-
mones, which in turn leads to a decrease in blood sugar levels
after a meal (17). This was clearly seen in the improvement of
2HPPBs after 12 weeks of omeprazole use in our study. Other
reasons for the improvement in glycemic status may be re-
lated to the direct effect of gastrin on glucose dependent in-
sulinotropic peptide and the secretion of glucagon-like pep-
tide 1 (GLP1) from small intestinal K and L cells, although
this has not yet been proven. A 2 to 3-fold increase in plasma
gastrin levels occurs after 24 to 32 weeks of PPI consumption
(14). However, 12 weeks of pantoprazole treatment in Singh’s
study was associated with a 50% increase in plasma gastrin
levels, which could lead to a further improvement in hyper-
glycemic status in longer use of PPIs.
One of the strengths of our study is that it is prospective and
RCT, which distinguishes the current study from other retro-
spective studies, as well as accurate inclusion and exclusion
criteria and review of various parameters that did not exist in
other studies. But the before-after design and lack of placebo
group is our limitation compared to other RCT studies.
5. Conclusion
Treatment with omeprazole increases insulin levels and de-
creases the levels of HbA1c, FBS, thus improving glycemic
status and can be combined with other drugs used to man-
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age DM, especially in patients with gastrointestinal prob-
lems, but more studies are needed. RCTs with placebo group,
larger sample size, use of other PPIs, and if possible, plasma
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Figure 1: Gender demographic chart of the study participants.
Figure 2: Comparison of mean fasting blood sugar and blood glucose 2 hours after meals before and after receiving omeprazole.
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Figure 3: Changes in HbA1C and insulin level following 12 weeks of omeprazole therapy.
Figure 4: Comparison of Homeostatic model assessment of Insulin resistance (HOMA-IR) and homeostatic model assessment of β-cell dys-
function (HOMA-B) indices before and after omeprazole administration.
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Table 1: Comparison of follow up group and loss of follow.
Status N Mean Std. Deviation P-Value
Age Follow-up 32 54.34 10.85 0.724
Lost to follow-up 8 52.87 8.32
BMI Follow-up 32 29.00 2.74 0.905
Lost to follow-up 8 28.87 2.03
HbA1C. Before Follow-up 32 8.11 0.96 0.298
Lost to follow-up 8 7.73 0.58
Insulin. Before Follow-up 32 13.09 5.65 0.845
Lost to follow-up 8 12.64 6.30
C-Peptide. Before Follow-up 32 2.94 0.98 0.548
Lost to follow-up 8 2.70 1.02
FBS. Before Follow-up 32 156.03 30.87 0.817
Lost to follow-up 8 153.25 26.76
2hppBs. Before Follow-up 32 241.78 64.35 0.715
Lost to follow-up 8 232.75 50.34
BMI: Body mass index; HbA1c: glycosylated hemoglobin; FBS: fasting plasma sugar; 2HppBS: 2 hours post prandial blood sugar.
Table 2: The education level of all study participants and the remaining follow up group.
Education level study participants Follow up group
None 3 2
Less than a high school diploma 20 16
High school diploma 12 11
Advance degree 5 3
Table 3: The effect of 12 weeks omeprazole therapy on glycemic parameters.
Parameter Before Omeprazole After Omeprazole P Value
HbA1C (%) 8.11±0.96 7.13±0.68 0.001
FBS (mg/dl) 156.03±30.87 146.90±23.88 0.01
2HppBs (mg/dl) 241.78±64.35 226.71±48.45 0.16
Insulin (µU/ml) 13.09±5.65 17.10±7.16 0.001
C-Peptide (ng/ml) 2.94±0.98 3.40±1.30 0.003
HbA1c: glycosylated hemoglobin; FBS: fasting plasma sugar; 2HppBS: 2 hours post prandial blood sugar.
Table 4: Comparison of our study results with Singh and colleagues’ study.
Singh’s study Our study
Parameter Pantoprazole (Before) Pantoprazole (After) Omeprazole (Before) Omeprazole (After)
HbA1c 7.9±1.2 6.8±1.2 8.11±0.96 7.13±0.68
FBS 126.3±10.3 109.2±13.0 156.03±30.8 146.90±23.8
2HppBs ———- ——— 241.7±64.3 226.7±48.4
Insulin 10.5±4.0 13.9±4.5 13.09±5.65 17.10±4.16
C-Peptide ———- ———- 2.94±0.98 3.40±1.30
Gastrin 54.4±14.0 75.6±15.1 ———- ———-
HOMA β-cell 75.0±55.8 105.1±52.9 54.41±27.09 79.24±45.32
HOMA-IR 3.9±1.4 3.8±1.7 5.02±2.42 6.19±2.52
HbA1c: glycosylated hemoglobin; FBS: fasting plasma sugar; 2HppBS: 2 hours postprandial blood sugar;
HOMA β-cell: homeostatic model assessment of β-cell dysfunction; HOMA-IR: Homeostatic model assessment of Insulin resistance.
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